Pharmaxis (PXS) - Progressing to Next Stage in Scarring and Myelofibrosis
PXS reported encouraging proof of concept data last month for its PXS-6302 skin scar treatment. PXS-6302 reduced the excess collagen content in...
431 Views
Pharmaxis (PXS) - PXS-5505 to Progress to JAK Combo Trial
PXS announced that it will accelerate plans to investigate its anti-fibrosis drug PXS-5505 in combination with JAK inhibitors in myelofibrosis (MF).
364 Views
PharmaEssentia GDS Issuance - Strong Revenue Growth and Narrowing Losses
Pharmaessentia Corp (6446 TT) aims to raise around US$412m (TWD12.6bn) via a GDS issuance. In this note, we will talk about the deal dynamics and...
954 Views
Pharmaxis (PXS) - Encouraging Initial Efficacy Data, Adding New Programs
It also recently added an externally-funded Phase II trial of PXS-4728 (handed back by Boehringer in 2020) in patients at high risk of Parkinson’s...
138 Views
Taxing Times For Australia
The Government's release of Re:think, its tax discussion paper, is a welcome development, designed to kick-start the conversation with the...
5.8k Views
No more insights